(HealthDay News) — The number of US adults with severe obesity increased from 2013 to 2023, according to a research letter published online Feb. 13 in the Journal of the American Medical Association.

Developed by the Serum Institute of India, the rBCG product, which has been modified to improve its immunogenicity and safety, was evaluated in phase 1/2 clinical trials in Europe in patients with ...

HealthDay News — The US Department of Agriculture (USDA) has granted conditional approval for a new bird flu vaccine for poultry. This new avian flu vaccine, developed by New Jersey-based Zoetis, was ...

Vimkunya is supplied as an injectable suspension; the vaccine is administered intramuscularly as a single 0.8mL dose.

HealthDay News — President Donald Trump signed an executive order withholding funding from schools and universities that require students to be vaccinated against COVID.

Significantly more patients with acute ischemic stroke achieved primary outcome of 0 or 1 on modified Rankin scale at 90 days ...

Investigators compared the outcomes of patients with type 2 diabetes who continued versus stopped metformin after progressing to stage 4 chronic kidney disease.

Increased risk seen with use of combined pill, progestin-only pills, combined vaginal ring, patch, and progestin-only implant ...

The US Employee Perspectives on Managing Chronic Conditions in the Workplace poll was conducted October 2 to 16, 2024, and included a nationally representative sample of the 1010 part-time and ...

The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application for zongertinib for the treatment of adult patients with ...

Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).

HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...